EFFECTS OF HOMOLOGOUS AND HETEROLOGOUS BOOSTER VACCINATIONS OF THE INACTIVATED DUAL-ADJUVANTED VACCINE VLA2001 AGAINST COVID-19 INCLUDING VARIANTS OF CONCERN: A PHASE 3 RANDOMIZED CLINICAL TRIAL

被引：1
|
作者：
Wressnigg, N. [1 ]
Taucher, C. [1 ]
Eder-Lingelbach, S. [1 ]
Querton, B. [1 ]
Krammer, M. [1 ]
Lilja, A. [2 ]
Hochreiter, R. [3 ]
Hoffmann, M. [4 ]
Poehlmann, S. [4 ]
Jaramillo, J. -C. [1 ]
机构：
[1] Valneva, Clin Dev, Vienna, Austria
[2] Valneva, Pre Clin R&D, Vienna, Austria
[3] Valneva, Clin Serol, Vienna, Austria
[4] Georg August Univ Gottingen, German Primate Ctr, Gottingen, Germany
来源：
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES | 2023年 / 130卷
关键词：
D O I：
10.1016/j.ijid.2023.04.059
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：S25 / S25
页数：1
相关论文
共 12 条
  • [1] Safety and immunogenicity of the inactivated whole-virus adjuvanted COVID-19 vaccine VLA2001: A randomized, dose escalation, double-blind phase 1/2 clinical trial in healthy adults
    Lazarus, Rajeka
    Taucher, Christian
    Brown, Claire
    Ramljak, Irena Corbic
    Danon, Leon
    Dubischar, Katrin
    Duncan, Christopher J. A.
    Eder-Lingelbach, Susanne
    Faust, Saul N.
    Green, Christopher
    Gokani, Karishma
    Hochreiter, Romana
    Wright, Johanna Kellett
    Kwon, Dowan
    Middleditch, Alexander
    Munro, Alasdair P. S.
    Naker, Kush
    Penciu, Florentina
    Price, David
    Querton, Benedicte
    Riaz, Tawassal
    Ross-Russell, Amy
    Sanchez-Gonzalez, Amada
    Wardle, Hayley
    Warren, Sarah
    Finn, Adam
    JOURNAL OF INFECTION, 2022, 85 (03) : 306 - 317
  • [2] Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial
    Taucher, Christian
    Lazarus, Rajeka
    Dellago, Hanna
    Maurer, Gabriele
    Weisova, Petronela
    Corbic-Ramljak, Irena
    Dubischar, Katrin
    Lilja, Anders
    Eder-Lingelbach, Susanne
    Hochreiter, Romana
    Jaramillo, Juan Carlos
    Junker, Helga
    Krammer, Michael
    Pusic, Petra
    Querton, Benedicte
    Larcher-Senn, Julian
    Hoffmann, Markus
    Poehlmann, Stefan
    Finn, Adam
    JOURNAL OF INFECTION, 2023, 87 (03) : 242 - 254
  • [3] Immunogenicity and safety of an inactivated whole-virus COVID-19 vaccine (VLA2001) compared with the adenoviral vector vaccine ChAdOx1-S in adults in the UK (COV-COMPARE): interim analysis of a randomised, controlled, phase 3, immunobridging trial
    Lazarus, Rajeka
    Querton, Benedicte
    Ramljak, Irena Corbic
    Dewasthaly, Shailesh
    Jaramillo, Juan Carlos
    Dubischar, Katrin
    Krammer, Michael
    Weisova, Petronela
    Hochreiter, Romana
    Eder-Lingelbach, Susanne
    Taucher, Christian
    Finn, Adam
    LANCET INFECTIOUS DISEASES, 2022, 22 (12): : 1716 - 1727
  • [4] Safety and immunogenicity of heterologous recombinant protein subunit vaccine (ZF2001) booster against COVID-19 at 3-9-month intervals following two-dose inactivated vaccine (CoronaVac)
    Liao, Yuting
    Chen, Yingping
    Chen, Bo
    Liang, Zhenzhen
    Hu, Xiaosong
    Xing, Bo
    Yang, Juan
    Zheng, Qianhui
    Hua, Qianhui
    Yan, Chuanfu
    Lv, Huakun
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [5] Effect of heterologous intranasal iNCOVACC® vaccination as a booster to two-dose intramuscular Covid-19 vaccination series: a randomized phase 3 clinical trial
    Venkateshwar Rao Akula
    Amit Suresh Bhate
    Chandrasekhar S. Gillurkar
    Jitendra Singh Kushwaha
    Ajeet Pratap Singh
    Chandramani Singh
    Anil Kumar Pandey
    Shivaraj K. K
    Sanjay K. Rai
    Krishna Mohan Vadrevu
    Communications Medicine, 5 (1):
  • [6] Immunogenicity and safety of a recombinant COVID-19 vaccine (ZF2001) as heterologous booster after priming with inactivated vaccine in healthy children and adolescents aged 3-17 years: an open-labeled, single-arm clinical trial
    Huang, Tao
    Hu, Qianqian
    Zhou, Xiang
    Yang, Huaiyu
    Xia, Wei
    Cao, Feng
    Deng, Minglu
    Teng, Xiaoxue
    Ding, Fan
    Zhong, Zaixin
    Gao, Lidong
    Sun, Jiufeng
    Gong, Lihui
    BMC INFECTIOUS DISEASES, 2024, 24 (01)
  • [7] A third high dose of inactivated COVID-19 vaccine induces higher neutralizing antibodies in humans against the Delta and Omicron variants: a Randomized, Double-Blinded Clinical Trial
    Yu Cao
    Xiaoli Wang
    Siqi Li
    Yuan Dong
    Yonghong Liu
    Jing Li
    Yanqing Zhao
    Yingmei Feng
    Science China(Life Sciences) , 2022, (08) : 1677 - 1679
  • [8] A third high dose of inactivated COVID-19 vaccine induces higher neutralizing antibodies in humans against the Delta and Omicron variants: a Randomized, Double-Blinded Clinical Trial
    Cao, Yu
    Wang, Xiaoli
    Li, Siqi
    Dong, Yuan
    Liu, Yonghong
    Li, Jing
    Zhao, Yanqing
    Feng, Yingmei
    SCIENCE CHINA-LIFE SCIENCES, 2022, 65 (08) : 1677 - 1679
  • [9] A third high dose of inactivated COVID-19 vaccine induces higher neutralizing antibodies in humans against the Delta and Omicron variants: a Randomized, Double-Blinded Clinical Trial
    Yu Cao
    Xiaoli Wang
    Siqi Li
    Yuan Dong
    Yonghong Liu
    Jing Li
    Yanqing Zhao
    Yingmei Feng
    Science China Life Sciences, 2022, 65 : 1677 - 1679
  • [10] N-protein vaccine is effective against COVID-19: phase 3, randomized, double-blind, placebo-controlled clinical trial
    Rabdano, Sevastyan O.
    Ruzanova, Ellina A.
    Vertyachikh, Anastasiya E.
    Teplykh, Valeriya A.
    Emelyanova, Alla B.
    Rudakov, German O.
    Arakelov, Sergei A.
    Pletyukhina, Iuliia V.
    Saveliev, Nikita S.
    Lukovenko, Anna A.
    Fakhretdinova, Liliya N.
    Safi, Ariana S.
    Zhirenkina, Ekaterina N.
    Polyakova, Irina N.
    Belozerova, Natalia S.
    V. Klykov, Vladislav
    Savelieva, Arina P.
    Ekimov, Aleksey A.
    V. Pokachalov, Konstantin
    Merkulov, Vadim A.
    Yudin, Sergei M.
    Kruchko, Daria S.
    Berzin, Igor A.
    Skvortsova, Veronika I.
    JOURNAL OF INFECTION, 2024, 89 (05)
12